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Abstract 
There is evidence from both in vitro and animal models that the consumption of edible mushrooms 
has beneficial effects on health. It is unclear whether similar effects exist in humans and which 
bioactive compounds are present. This review synthesizes the evidence on the world’s most 
commonly consumed mushroom, Agaricus bisporus to (i) examine its effect on human health 
outcomes; and (ii) determine the nutrient density of its bioactive compounds, which may explain 
their health effects. A systematic literature search was conducted on the consumption of A. 
bisporus, without date and study design limits. Bioactive compounds included ergosterol, 
ergothioneine, flavonoids, glucans and chitin. Two authors independently identified studies for 
inclusion and assessed methodological quality. Beneficial effects of A. bisporus on metabolic 
syndrome, immune function, gastrointestinal health and cancer, with the strongest evidence for the 
improvement in Vitamin D status in humans, were found. Ultraviolet B (UVB) exposed mushrooms 
may increase and maintain serum 25(OH)D levels to a similar degree as vitamin D supplements. A. 
bisporus contain beta-glucans, ergosterol, ergothioneine, vitamin D and an antioxidant compound 
usually reported as flavonoids; with varying concentrations depending on the type of mushroom, 
cooking method and duration, and UVB exposure. Further research is required to fully elucidate the 
bioactive compounds in mushrooms using vigorous analytical methods and expand the 
immunological markers being tested. To enable findings to be adopted into clinical practice and 
public health initiatives, replication of existing studies in different population groups is required to 
confirm the impact of A. bisporus on human health. 
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1. Introduction
Although commonly regarded and consumed as a vegetable, mushrooms are members of the Fungi 
kingdom and offer a unique nutritional profile. Biologically distinct to both plants and animals, 
mushrooms are rich in micronutrients that are normally found in vegetables, meats and grains [1]. 
These include riboflavin, niacin, pantothenic acid, copper, phosphorus, selenium, fibre-associated 
monosaccharides and polysaccharides, and the sulphur-containing amino acid ergothioneine [1, 2].  
Mushrooms are one of the only natural vegetarian sources of both vitamin B12, which is bacteria-
derived [3], and vitamin D, which is produced by the conversion of ergosterol to ergocalciferol after 
exposure to ultraviolet (UV) light [4]. 
There is a growing body of evidence that suggests consuming several mushroom species, either as a 
food or as extracts, may improve physical and mental health [5, 6]. Mushrooms are rich in bioactive 
compounds, particularly ergothioneine, ergosterol, vitamin D, beta-glucan and selenium, and these 
bioactive compounds have been favourably linked to immune function [7, 8], glycaemic control [9, 
10], weight management [11], lipid profile [12, 13], blood pressure [14], bone density [15], gut 
health [16], cancer [17, 18] and cognitive function [19].  These health benefits are thought to be 
largely a result of the enhancement of cellular immunity to produce immunomodulatory, anti-
carcinogenic, anti-microbial and hypocholesterolemic effects [5], and due to their effects on the 
gastrointestinal microbiota (19). 
Despite the growing body of evidence linking mushrooms’ nutritional uniqueness to beneficial health 
effects, existing narrative reviews have found limited evidence in human studies. In 2012, Roupas et 
al. [5] concluded that while mushrooms of many different species demonstrated numerous health 
benefits within in vitro and in vivo animal models, there was insufficient evidence to confirm similar 
effects in humans due to limitations in study design, sample size and the indirectness of the 
evidence [5]. Other narrative reviews investigating the role of beta-glucans in mushrooms [20] and 
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immunomodulatory activities of mushroom polysaccharides [21] have also found limited research in 
humans. Since these narrative reviews were published, interest into the therapeutic properties of 
edible mushrooms in human models has grown. Therefore, a broad systematic synthesis of the 
evidence reporting the health effects of edible mushrooms in humans and their bioactive 
compounds that support these effects is warranted. 
Due to the large variety of mushroom species available for human consumption, a focus on those 
that are most abundant and frequently consumed by humans will have the greatest translational 
value. The most commonly consumed mushrooms worldwide belong to the Agaricus bisporus 
species, which includes white button mushrooms (WBM), brown button mushrooms (BBM), 
portobello and cremini mushrooms [1]. Therefore, the aim of this scoping literature review was to 
synthesize the evidence on A. bisporus mushrooms to (i) examine its effect on human health 
outcomes; and (ii) determine the nutrient density of its bioactive compounds, which may explain 
their health effects. 
2. Methods
The review protocol was developed using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [22], PRISMA Extension for Scoping Reviews (PRISMA-ScR) [23] 
and was prospectively registered at PROSPERO (still awaiting processing). 
2.1. Eligibility criteria 
Table 1 highlights the eligibility criteria for the study selection. Studies were deemed eligible if they 
were original primary research articles conducted in human populations, reported on whole or 
processed (e.g. dried extract) mushrooms from the A. bisporus species, were consumed orally, and 
reported a health outcome. All physical and mental health outcomes were considered for inclusion. 
Prospective cohort and cross-sectional studies on health outcomes in humans were considered if the 
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dietary intake from mushrooms was measured, even if the mushroom type (e.g. whole mushroom or 
extract) was unspecified. Studies reporting on bioactive compounds were also included if they 
reported on A. bisporus mushrooms and measured ergosterol, ergothioneine, flavonoids, glucans 
(alpha- or beta-glucans) or chitin. 
2.2. Search strategy 
A systematic search for publications was conducted (25th June 2019), using the electronic databases 
MEDLINE, EMBASE, Scopus, CINHAL and The Cochrane Library, without date limits (Table S1). To 
identify publications that reported on the consumption of A. bisporus mushrooms, the following 
keywords were searched (with special features in parentheses): Agaricus (exp/), Agaricus bisporus 
(exp/), A bisporus (exp/), white button mushroom (exp/), button mushroom (exp/), common 
mushroom (exp/), cultivated mushroom (exp/), champignon (exp/), cremini (exp/), cremini (exp/), 
portobello (exp/) (Table S1). Keywords were searched for as free text in the title, abstract and 
subject headings. Study population and outcomes records were combined using the Boolean 
operator “AND”. Additional publications were identified from references in original papers. 
2.3. Selection process 
All records identified were first assessed for eligibility based on information contained in the title, 
abstract, and description/MeSH heading by two independent reviewers (KA, ED, TC or FFM), after 
which the inclusion and exclusion criteria were applied (Table 1). This process was completed using 
Covidence systematic literature review software [Veritas Health Innovation, Melbourne, Australia] 
[24]. The full text of all studies that appeared to meet the eligibility screening were retrieved and 
subjected to a second assessment for relevance by the same two reviewers (Table 1). Any difference 
in assessments that arose between reviewers was discussed in the first instance or resolved by a 
third independent reviewer (FFM). 
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Human research studies were then assessed for methodological quality in duplicate by two 
independent reviewers (KA and ED) using the Quality Criteria Checklist for Primary Research in the 
Academy of Nutrition and Dietetics Evidence Analysis Manual [25]. The Quality Criteria Checklist 
included four relevance questions that addressed applicability to practice and ten validity questions 
that addressed scientific reliability, including confounding, study quality and heterogeneity.  The 
Quality Criteria Checklist enabled a systematic, objective rating (positive, negative or neutral) to be 
given to each study and was used to confirm agreement among independent reviewers. ‘Positive’ 
studies were of the highest quality, with most answers to the validity questions being positive, 
followed by ‘neutral’ studies. ‘Negative’ studies were of the lowest quality, with most of the answers 
to the validity questions being negative. Once again, any difference in assessments were resolved, if 
necessary, by a third independent reviewer (FFM). The internal validity of studies which reported 
biochemical analysis of mushrooms was not performed as critical appraisal tools do not exist for this 
study design. 
2.4. Data extraction 
Data were extracted from all included studies into a Microsoft Excel [Version 1908; Excel for Office 
365] spreadsheet by one investigator (KA or ED) and checked for accuracy by another investigator
(KA or ED). Data extracted were study and participant characteristics, baseline, follow-up, washout 
period, run-in period, test product, control product, dosage, measurement method, change in 
outcome, and p-value for between group comparisons. Data extracted for bioactive studies included 
source of mushrooms, whether mushrooms were cultivated or wild, storage conditions, extraction 
and measurement technique used, amount of the bioactive reported and units of measurement. For 
studies reporting ergosterol, vitamin D was also extracted if reported. Original authors were 
contacted to confirm any missing data [26-28]. If original authors could not be contacted, data were 
retrieved using manuscript figures [27] or excluded [26, 28]. 
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3. Results
3.1. Description of studies 
The systematic search strategy identified 9,811 records, of which 68 were eligible for inclusion (n=15 
human studies, n=53 biochemical studies; Figure 1). 
3.1.1. Health outcomes 
A total of 15 human trials reported on consumption of A. bisporus mushrooms and physical health 
outcomes [29-43], and none reported on mental health or cognitive function. The study 
characteristics and methodological quality of these included studies are shown in Table 2. The 
majority (73%) of studies were randomised controlled trials (RCTs) [29-36, 39, 40, 43]). Other study 
designs included a non-RCT [41], a secondary analysis of a RCT which presented pooled data from 
two intervention groups in a pre-post study design format [42], a Phase 1 Clinical trial [38], and a 
retrospective case-control study [37]. The reported health outcomes were vitamin D status (4 
studies) [29-32], inflammation (2 studies) [33, 34], satiety (2 studies) [35, 40], cancer (2 studies) [37, 
38], gastrointestinal health (2 studies) [39, 40], cholesterol [34, 41], diabetes risk factors [42], and 
immunology [43]. Studies were mainly conducted in the United States of America (USA) (9 studies) 
[29, 30, 32, 34-36, 38, 39, 42], and others were from Germany [31], Netherlands [33], China [37], 
Japan [40], Iraq [41], and Australia [43]. Only one study reported minor adverse effects (abdominal 
bloating), but had no participant withdraw. 
Studies were mainly conducted in adults, with one study on male teenage athletes [32]. Most of the 
intervention studies used ‘healthy’ populations (8 studies) [29-31, 34-36, 39, 43], with the remaining 
conducted in adults with hypercholesterolemia [33], metabolic syndrome [42], insufficient Vitamin D 
levels [32], older adults with problematic halitosis and body odour [40], and cancer [37, 38] (Table 
2).  
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Using the Quality Criteria Checklist for Primary Research (Table S2), six studies received a positive 
quality rating (i.e. defined as having a high level of internal validity and low risk of bias across the 
study) [29, 31, 37, 38, 42, 43], six studies received a neutral rating (i.e. unclear levels of internal 
validity and bias) [32-36, 39], and three studies received a negative rating [30, 40, 41]. Interventions 
were generally well described with clearly defined outcomes. Objective biomarkers were utilised 
across studies, with the exception of studies that had self-reported measures of satiety [35, 36] and 
gastrointestinal health outcomes [39, 40]. 
3.1.2. Bioactive compounds 
A total of 41 studies reported the concentration of bioactive antioxidant compounds (ergosterol, 16 
studies [44-59]; ergothioneine, 4 studies [48, 60-62]; flavonoids, 22 studies [63-84]) and 16 reported 
concentrations of polysaccharides (glucans, 9 studies [27, 80, 84-91]; chitin, 7 studies [27, 87, 90, 92-
95]) in A. bisporus mushrooms (Table 3). From the 16 papers that reported ergosterol, five also 
reported Vitamin D2 (25(OH)D2) [46, 48-51]. Mushroom varieties included WBM (47 studies) [27, 46-
56, 59-66, 68-87, 89-95], portobello (8 studies) [49, 57, 58, 60, 61, 85, 87, 88], BBM (7 studies) [47, 
48, 54, 55, 67, 79, 89], and cremini (6 studies) [49, 60, 61, 85, 87, 88] mushrooms. The majority of 
studies (79%) reported only one mushroom type, with WBM being the most common (68%), and 
two studies did not specify the type of mushroom used [44, 45]. Mushrooms were mainly cultivated 
(51 studies) [27, 46, 48-58, 60-83, 86-95] and sourced from Europe (24 studies) [27, 44, 45, 50, 52, 
53, 55-58, 64, 67, 69, 73, 74, 78, 79, 86, 88-90, 93-95] and Asia (19 Studies) [51, 59, 62, 63, 65, 66, 
68, 71, 72, 75-77, 80-84, 87, 91]. Other regions included the Americas (6 studies) [48, 49, 60, 61, 70, 
85], Canada (3 studies) [46, 47, 54] and the United Kingdom (1 study) [92].  
3.2. Impact of A. bisporus mushroom intake on human health 
3.2.1. Serum vitamin D 
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Studies that reported on the bioavailability of vitamin D from UVB-exposed mushrooms used fresh 
mushrooms [29, 31], dried mushroom extract [30] and mushroom powder [32]. Doses of vitamin D 
ranged from 8.8 µg/day (352 IU/day) [29], up to 28,000 IU/day (700 µg/day) [31], and study 
durations ranged from 5 to 12 weeks. A significant increase in serum 25(OH)D2 was reported in all 
four RCT studies [29-32], alongside a decrease in serum 25(OH)D3 reported in two studies [29, 32], 
(p<0.001 for all). Three studies showed a significant increase in total serum 20(OH)D (p<0.001 for all) 
[30-32], and only one study specifically screened people for low levels of vitamin D at baseline [32]. 
When UVB-exposed mushroom extracts were compared to a daily vitamin D2 or D3 supplement 
(2000 IU/day; 50 µg/day) across a 12-week intervention, no significant differences in overall 
25(OH)D levels between the groups were found [30]. At doses of 2000 IU/day, UVB-exposed 
mushrooms were equivalent to a supplement at increasing total 25(OH)D levels. 
3.2.2. Inflammatory markers 
Three studies reported on inflammatory markers [33, 34, 42]. In healthy young women, both 8 g and 
16 g doses of mushroom powder increased serum ergothioneine and decreased oxygen radical 
absorbance capacity (ORAC) [34]. Alternatively, in a 16-week uncontrolled pre-post study using a 
cooked mushrooms intervention (100 g/day), both serum ergothioneine and ORAC increased 
(p=0.03) [42]. When cytokine production was measured after 5 g/day of -glucans from mushroom 
extract consumed across a 5-week intervention, tumour necrosis factor (TNF)-alpha decreased 
compared to the control (p=0.017) [33]. However, there were no effects on any other inflammatory 
markers measured (i.e. interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, interferon-, serum 
creatinine). 
3.2.3. Satiety 
Two studies assessed the impact of dietary mushrooms on satiety, and findings were inconsistent 
[35, 36]. In 35 young adults (age 23±4 years), mushroom consumption was associated with lower 
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hunger (p=0.045), greater fullness (p=0.05) and decreased prospective food consumption (p=0.03) 
compared with a protein-matched beef portion [35].  However, no change in energy intake was 
observed [35]. Alternatively, in a different sample of mixed-race adults from the USA (n=47; age 
mean (range) 35.5 (18-62) years) mushroom intake was not associated with changes in subjective 
satiety when compared to a volume-matched, rather than energy-matched, portion of beef [36]. The 
replacement of mushrooms for beef resulted in a decrease in the total fat and energy intake (total 
fat 41.10.4 g vs. 10.20.2 g, p<0.001; energy 201270 kcal vs. 164065 kcal, p<0.001) of the meal, 
and the lower energy intake from the meal was only partially compensated for at the other eating 
occasions (11.412.0% energy; 7.47.7% total fat) [36]. 
3.2.4. Gastrointestinal health  
Consumption of fresh mushrooms [39] and a mushroom extract [40] both showed beneficial effects 
on stool weight, microbiota, bowel strain, faecal odour and halitosis (Table 2). No changes were 
observed in markers of bacterial fermentation (breath H2, faecal pH and faecal short chain fatty 
acids) [39] or bowel regularity [40], compared to the control. 
3.2.5. Cancer 
The association between human consumption of A. bisporus mushrooms and cancer was assessed in 
a case control study [37] and a Phase 1 Clinical Trial [38]. In the case-control study of 1000 females 
from China (age 59±6 years), consumption of more than 2 g per day of WBM reduced the odds of 
ovarian cancer by 32% (adjusted OR 0.68 (95% CI, 0.52-0.89) [37]. In a sample of prostate cancer 
patients, mushroom extract at increased doses (4 g to 14 g extract daily; equivalent to 40 g to 140 g 
fresh WBM) was associated with decreased total prostate specific antigen (PSA) levels in 36% of 
patients, with stable PSA levels or no effect in the remaining patients [38]. Minimal side effects were 
reported and mostly limited to Grade 1 abdominal bloating [38]. 
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3.2.6. Metabolic markers 
Two studies reported on metabolic markers of health [41, 42]. WBM cooked in olive oil (2 g/kg body 
weight/day) were associated with significantly lower glucose, total cholesterol, low-density 
lipoprotein, triglycerides and body weight, and higher high-density lipoprotein, compared to the 
control (p<0.05 for all) [41]. However, baseline values were not reported, and the olive oil was only 
delivered to the treatment group. In a second sample of adults with at least two features of the 
metabolic syndrome, adiponectin increased after daily consumption of 100 g of cooked mushrooms 
over the 16-week intervention (7.93.2 g/mL baseline; 8.83.5 g/mL 16 weeks, p=0.03) [42]. 
3.2.7. Immune function 
The effect of cooked WBM (100 g/day for 7 days) on salivary IgA secretion was measured in 24 
healthy adults (age 41.4±11.3 years) [43]. Compared to their usual diet, 100 g of cooked WBM intake 
for seven days was associated with increased serum IgA osmolarity (p<0.0001), secretion rate 
(p<0.0005), and concentration (p<0.0005) [43]. These findings indicate a potential benefit for 
mucosal immunity. 
3.3. Concentration of bioactive compounds in A. bisporus 
3.3.1. Flavonoids 
The majority (95%) of studies reported the total flavonoid content of whole mushrooms, and one 
study reported individual flavonoids [64] (Table 3). Two studies measured the cap and stipe (i.e. the 
stalk) separately for WBM [63, 79] and BBM [79], and five studies investigated the effect of cooking 
on flavonoid content [69, 71, 76, 77, 81]. WMB had the highest concentration of catechins (396.00 
ug/g) and myricetins (11.75 ug/g), and low to negligible quantities of quercetin, kaempferol, 
naringenin and resveratrol present (0.25-1.75 ug/g) [64]. Cooking mushrooms reduced flavonoid 
concentrations and flavonoid concentration for raw mushrooms was the highest across all studies 
[69, 71, 76, 77, 81]. Cooking methods assessed included blanching [69], frying [71, 76], boiling [76, 
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77, 81], microwaving [76, 77], steaming [76, 77] and pressure cooking [76, 77]. Only two studies 
measured the effect of cooking time, on flavonoid content [71, 76]. For both boiling and frying, 
flavonoid content was reduced with cooking time (6 minutes) [71, 76]. For shorter cooking times (1.5 
minutes), microwaving retained the most flavonoids compared to boiling or steaming (70.8%, 60.4% 
and 55.4% respectively) [76]. When cooking time was extended to six minutes, microwaving retained 
the least flavonoids compared to other cooking methods (20.8% microwaving, 48.5% boiling, 68.3% 
steaming) [76]. 
The mushroom cap had a greater concentration of flavonoids than the stipe. Four out of five 
analyses from two studies reported a mean of 28.1% greater flavonoid concentration in the WBM 
cap (range: 4.5 – 58.4%), compared to the stipe [63, 79]. For BBM, the difference between the cap 
and stipe differed according to the solvent used for the analysis, with the water solvent showing a 
greater concentration in the cap, and the 50% water-ethanol showing a greater concentration in the 
stipe [79]. Only one study reported on flavonoids in both WBM and BBM, with the water solvent 
showing higher concentrations of flavonoids in the BBM, and water-ethanol solvent showing a 
greater concentration in WBM [79]. Majority of studies (75%) used colorimetric assays [63, 65-68, 
70-76, 78, 79, 81], while the remainder used spectrometry (15%) [69, 77, 80], high performance
liquid chromatography (5%) [64] or an unspecified method (10%) [82, 83]. None of the studies 
reported on flavonoid concentrations by mushroom maturity (e.g. WBM compared to Portobello). 
3.3.2. Ergosterol and Vitamin D 
Ergosterol was measured in 16 studies [44-59]. In addition to ergosterol, vitamin D2 was also 
measured in five of those studies [46, 48-51]. Most studies (67%) that reported on ergosterol and 
vitamin D content used UVB-exposed mushrooms [46, 48-50]. The range of ergosterol 
concentrations in UVB-exposed whole WBM and BBM were 579.5 mg/100 g – 633.4 mg/100 g [46, 
54] and 722.0 mg/100 g – 769.0 mg/100 g [54], respectively (Table 3). No studies reported
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ergosterol in UVB-exposed extracts. In non-UV-exposed whole WBM and BBM, the average 
ergosterol concentration was 714.3 mg/100 g (range 56.3 – 1740 mg/100 g) [45-47, 49-51, 53, 54, 
56] and 334.5 mg/100 g (range 203.0 – 466.0 mg/100 g) [47, 54], respectively. In non-UV-exposed
WBM and BBM extracts, the range of ergosterol concentration was 4 – 3672 mg/100 g [44, 48, 52, 
55] and 26.4 – 620 mg/100 g [48, 55], respectively. Exposure to UVB light over time consistently
increased vitamin D2 content and decreased ergosterol concentrations [49, 54]. 
Both BBM and cremini mushrooms had a marginally higher quantity of ergosterol compared to WBM 
in two studies (BBM 466 mg/100 g vs. WBM 341 mg/100 g [47]; cremini 61.4 mg/100 g vs. WBM 56.3 
mg/100 g [49]. None of the studies investigated the effect of cooking method or mushroom maturity 
on ergosterol content. Except one study which compared the portobello cap against whole WBM 
[49] and found a marginally higher concentration of ergosterol in the portobello cap (62.1 mg/100 g)
compared to the WBM (56.3 mg/100 g) [49]. 
3.3.3. Ergothioneine 
Four studies measured ergothioneine content [48, 60-62]. One used both WBM and BBM extracts 
[48], while the remaining studies used whole mushrooms [60-62]. Whole mushrooms contained an 
average ergothioneine content of 0.43±0.25 mg/g. There were no clear trends among the two 
studies that compared the ergothioneine content by type of whole mushroom (whole WBM, cremini 
and portobello mushrooms) [60, 61]. However, WBM extract had a greater concentration of 
ergothioneine (0.81-0.92 mg/g) than BBM extract (0.37-0.48 mg/g) [48]. None of the studies 




Nine papers measured and reported on glucans as either total [80, 84, 87-89, 91], alpha- [27, 80, 84, 
87-89, 91], and/or beta- [27, 80, 84-89, 91]. Glucans were reported using a variety of methods (%
w/w, %, and g/100 g), making direct comparisons across studies difficult. When total, alpha- and 
beta-glucans were compared across the cap and stipe of WBM and BBMs, a higher concentration of 
glucans was reported in the stipe [89]. Studies which measured both alpha and beta-glucans 
reported that the most prevalent glucans present in mushrooms are beta-glucans, which account for 
(mean ± SD) 75.0±17.8% of the total glucan concentration [80, 84, 89, 91]. BBM had a marginally 
higher concentration of glucans than WBM [89]. No differences in beta-glucan concentration was 
reported by mushroom maturity or cooking method [85], and all studies used whole mushrooms. 
3.3.5. Chitin 
Chitin was measured in seven studies using WBM [27, 87, 90, 92-95], with high variability in reported 
values. Chitin content ranged from 0.005 g/100 g to 1.2 g/100 g for whole mushroom [27, 87, 90], 
6.4% to 42% in the stipe [92, 93, 95], 7.2% to 7.4% in the cap [93, 95], 5.9% gills [93] and 0.005 g/100 
g for the extract [94]. Cooking increased chitin content regardless of preparation technology, with 
comparable values in fresh and canned samples (fresh: raw 0.60.04 g/100 g vs. cooked 0.70.04 
g/100 g; deep frozen: raw 0.340.01 g/100 g vs. cooked 0.520.02 g/100 g; canned: raw 0.610.05 
g/100 g vs. cooked 0.740.06 g/100 g) [90]. No studies measured chitin in other mushroom types. 
4. Discussion
This scoping literature review systematically summarised the evidence from human intervention 
trials and biochemical studies that reported on the health effects and bioactive compounds in A. 
bisporus mushrooms. Results confirmed that A. bisporus mushrooms are a rich source of beta-
glucans, antioxidants and vitamin D, with a wide variability in values reported by mushroom type, 
cooking time and method, and exposure to UVB across studies.  Several beneficial effects of A. 
bisporus consumption exist for metabolic syndrome, gastrointestinal health and cancer, with the 
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strongest evidence of a health effect on improving vitamin D status of individuals. All studies 
reported that the consumption of UVB-exposed mushrooms was as effective at increasing and 
maintaining total serum 25(OH)D levels as vitamin D supplements, in individuals with and without 
vitamin D deficiency at baseline. Despite the wide range of health benefits reported, the evidence is 
still quite limited and further research is warranted, specifically for inflammatory and immune 
function where results are promising. 
The biologically distinct and nutritionally unique properties of mushrooms make them a powerful 
food choice to improve human health. Unlike plants, mushrooms have high concentrations of 
ergosterol in their cell walls [4], and when both fresh and dried varieties of mushrooms are exposed 
to UVB radiation, ergosterol is transformed to pre-vitamin D2, then converted to vitamin D2 [30, 96]. 
Findings confirm UVB-exposed mushrooms contain vitamin D2 in a very bioavailable form that is 
relatively stable during storage and cooking, making them an ideal non-animal food source of 
vitamin D. Mushrooms also contain significant proportions of beta-glucans. We found that beta-
glucans accounted for approximately 75% of total glucan concentrations in A. bisporus mushrooms 
with a volume of 8-12 g/100 g dry weight, which is substantially higher than the 3-8 g/100 g dry 
weight found in oats, 1.3-2.7 g/100 g dry weight in rye, and 2-20 g/100 g dry weight in barley. A 
number of international food governing bodies (including Food Standards Australia New Zealand, 
U.S. Food and Drug Administration, European Food Safety Authority, Health Canada’s Food 
Directorate, and Singapore Food Agency) have approved a high level health claim based on the 
relationship between the consumption of 3 g of beta-glucans (from oats or barley) and blood 
cholesterol, with no such claim available for mushrooms. Given the significant proportions of beta-
glucans reported in mushrooms, further research in this area is warranted to confirm the potential 
health effects induced by beta-glucans from mushrooms specifically. 
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Studies identified by this review suggest that the consumption of A. bisporus mushrooms may 
improve both components of the metabolic syndrome and gastrointestinal health. However, the 
only study that measured markers of metabolic syndrome provided mushrooms alongside olive oil, 
which exerts its own beneficial effect on human health [97]. The impact of mushrooms on satiety 
was inconsistent, which is likely a result of the lack of consistent comparator groups used (i.e. 
volume matched vs. energy matched portion of beef). While whole mushrooms and extracts were 
associated with bowel function, further research is required to explore if these effects are linked to 
any further health improvement as existing research did not identify any change in short chain fatty 
acids or bacterial fermentation.  
Two included studies reported that A. bisporus mushrooms reduced the risk and progression of 
ovarian and prostate cancers, respectively. This suggests that these mushrooms may have a role as 
adjuvant therapy for cancer treatment. The mechanism of action for this effect may be related to 
the immunomodulating and anti-tumour effects of beta-glucans, ergothioneine and ergosterol [5]. 
Beta-glucans have been shown to have immune-stimulating effects [20, 21], and ergothioneine is an 
immune modifier with antioxidant and cytoprotective properties [98, 99]. This review found that 
consumption of whole WBM improved mucosal immunity in one study via increased serum IgA 
osmolarity and adiponectin [42], which may have a role in the prevention of malignancy and 
improved prognosis [100]. Decreased levels of ergothioneine in both blood and plasma have been 
observed in neurogenerative, cardiovascular and kidney diseases [99], while increased ergothioneine 
concentrations may beneficially modulate the tumour microenvironment [101]. Similarly, ergosterol 
is an immunologically active lipid that can induce pyroptosis [102]. Although included studies 
regarding the effect of human A. bisporus mushroom consumption on immunity and cancer had high 
internal validity, further robust RCTs are required to confirm their cancer preventative and 
treatment effects in diverse samples alongside traditional therapies. 
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A large number of published studies reported the presence of flavonoids in A. bisporus mushrooms. 
These highlight large variability in the measurement of total flavonoids, ranging from as little as 5.68 
mg rutin equivalents per 100 g [80], up to 1,636 mg per 100 g [83] in whole WBM. Estimates of daily 
flavonoid intake from across USA, European and Australian databases range from 209 mg to 1,017 
mg per day [103]. Recent evidence suggests that mushrooms may not contain flavonoids at all due 
to (i) the absence of genes required for their biosynthesis, and (ii) the lack of flavonoids detected 
when using analytic methods with higher levels of sensitivity and specificity such as high-
performance liquid chromatography versus colorimetric assays [104]. Currently, there are no 
validated methods for the identification and quantification of flavonoids in foods and plants, and 
thus quantification of flavonoids has been inconsistent between studies [105]. Gil Raminez et al. 
(2016) provide convincing evidence to suggest that another compound is being detected by assays 
claiming to detect flavonoids [104]. They showed that ergosterol demonstrated cross-reactivity with 
quercetin in a colorimetric assay, giving a positive reading in the detectable range when no quercetin 
was present [104]. As the majority (75%) of studies in this review measured flavonoids using 
colorimetric assays, caution is required when interpreting these values. Although flavonoids may or 
may not be present in mushrooms, a strong correlation between total flavonoids and antioxidant 
activity has been found [61]. Therefore, whatever the measured compound/s is, it has biological 
activity similar to that of flavonoids in vitro. If not a flavonoid, the compound could be ergosterol, as 
ergosterol from BBM and WBM has been highly correlated with total antioxidant activity (R2=0.89) 
[47] and could account for the antioxidant activity previously observed [61]. In turn, it may further
contribute to the cancer preventative effects of A. bisporus mushrooms. 
4.1. Implications for future research 
Opportunities exist for future research to confirm the causative relationship between the 
consumption of whole WBM versus extracts on human inflammatory and immune function, and its 
anti-cancer effects. Prior to being adopted into clinical practice and public health initiatives, 
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replication of existing studies in other population groups is required to confirm the impact of A. 
bisporus mushrooms on human health including satiety, gastrointestinal function including its effect 
on the microbiota, and metabolic syndrome. Initial human studies are required to replicate findings 
from in vitro and animal studies which suggest A. bisporus mushrooms may improve mental health 
and cognitive function, as none conducted in humans have reported on these health outcomes. 
Further research is required to fully elucidate the bioactive compounds in mushrooms using vigorous 
analytical methods, such as nuclear magnetic resonance spectroscopy, and expand the 
immunological markers and bioactive compounds being tested. 
4.2. Limitations 
The strengths of this review relate to the broad systematic literature search strategy used to identify 
the available evidence to answer the research question.  This is the first review to systematically 
synthesize the evidence from published human trials on A. bisporus mushroom specifically, and its 
consumption on health outcomes, while further reporting on the bioactive compounds that may 
explain these effects. This review is further strengthened by the development of and adherence to 
an evidenced based protocol and comprehensive evaluation of the methodological quality of 
included human studies. It is limited by many studies that reported inadequate details related to 
sample size or power calculations. The lack of such details may confound data particularly relating to 
the reliability of effect sizes. There was large variability in bioactive measurements reported in 
mushrooms, which may be due to differing analytic methods with varying degrees of sensitivity and 
specificity. Lastly, despite a growing interest in the relationship between mushrooms and health, 
only a small number of studies (< 4 studies) have been published for each health outcome, despite 
over 300 narrative reviews having been published on mushrooms and health using in vitro and 
animal models. This reduces confidence in the reported effects and limits the generalisability of the 
conclusions to the general population. 
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5. Conclusion
A. bisporus mushrooms are sources of beta-glucans, ergosterol, ergothioneine, vitamin D and an
antioxidant compound usually reported as flavonoids; with varying concentrations depending on the 
type of mushroom, cooking method and duration, and UVB exposure.  UVB-exposed mushrooms 
increase and maintain serum 25(OH)D levels to a similar degree as vitamin D supplements. Further, 
the evidence shows A. bisporus may lower the risk of cancer, and could potentially improve 
metabolic syndrome, immune function and gastrointestinal health.  Due to the small number of 
studies examining each health outcome and the lack of replication of reported results, further 
research is required to confirm these effects on health to enable findings to be adopted into clinical 
practice. 
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Table 1. Inclusion and exclusion criteria for the selection of studies 
Inclusion criteria Exclusion criteria 
Studies on A. bisporus mushrooms in human 
populations of any age and health effect, 
without date limits 
Studies published in languages other than 
English 
Studies using A. bisporus mushrooms in whole 
or processed (e.g. dried extract) form 
Studies where A. bisporus mushrooms were not 
consumed orally 
Studies conducted in any country Studies in animals 
Any study design Studies in duplicate populations 
Studies reporting data in a format that enabled 
data specific to mushrooms to be extracted 
Lack of a random sample 
Studies reporting ergosterol, ergothioneine, 
flavonoids, bioactive polysaccharides (alpha 
and beta glucans) and chitin in A. bisporus 
mushrooms 
Studies solely reporting other bioactive 
compounds in A. bisporus mushrooms 
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Figure 1.  PRISMA study flow chart
Records identified through 
database searching  






























 Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed 
(n = 5,707) 
Records screened 
(n = 5,707) 
Records excluded based 
on title and abstract  
(n = 4,673) 
Full-text articles excluded, 
with reasons  
(n = 969) 
Not an outcome (n = 420) 
Preclinical studies (n = 260) 
Could not access full-text (n = 124) 
Not a study (n = 68) 
Not in English (n = 61) 
Duplicate article (n = 36) 
Full-text articles 
assessed for eligibility 
(n = 1,037) 
Studies included in 
qualitative synthesis 
(n = 68) 
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Table 2. Studies using Agaricus bisporus mushrooms or extracts derived from Agaricus bisporus mushrooms and measuring health outcomes in 
humans 
Author, year, 
country Study aim 
Study Design, 














(+ Ø –) 
Vitamin D  
Stephensen, 
2012, USA 
To evaluate the 
effects of consuming 
UV-exposed white 
button mushrooms 
(A. bisporus) on the 




n: 9/10/10 (8.8 
µg D2/17.1 µg 
D2/control)  
(3% attrition) 




cooked mushrooms (87.9 
g/day) delivering 8.8 µg 
OR 17.1 µg D2/day  
Comparator: Non UV-
exposed cooked 
mushrooms (87.9 g/day) 














to 25(OH)D2 but 







Serum 25(OH)D2 ↑ (p<0.05) 
Serum 25(OH)D3 ↔ 
Serum 25(OH)D (total) ↔ 
Serum 24,25(OH)D3 ↔ 
17.1 µg D2/day: 
Serum 25(OH)D2 ↑ (p<0.05) 
Serum 25(OH)D3 ↓ (p<0.05) 
Serum 25(OH)D (total) ↔ 

















12 w 35 y 
75% f 
Healthy 
Intervention: Dried white 
button mushroom extract 
(2000 IU D2/day) 
Comparator: Supplement 
2000 IU D2/day OR 2000 
IU D3/day 






















To investigate the 
bioavailability of 
vitamin D2 from UV-
exposed mushrooms 
in humans, in 













(28,000 IU D2/day) 
OR Non-UV-exposed 
cooked mushrooms (60 IU 




mushrooms (60 IU D2/day 
28,000 IU D2/day: 













was effective in 
improving 





+ placebo supplement) 60 + 28,000 IU D2/day: 













muscle function and 
attenuate exercise-
induced muscle 
damage in low 
vitamin D status high 













(600 IU D2/day) 
Comparator: Placebo 
























Calvo, 2016, USA To estimate the 
impact of adding 
white button 
mushrooms to daily 









cooked mushrooms (100 
g/day) 
Comparator: Supplement 
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Intervention: 200 mL 
juice/day containing 5 g/day 
α-glucans extracted from 
white button mushrooms 





























effect on IL-1b 
and IL-6 was 
observed. No 
obvious Th1–
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decreased 
production of IL-
12 and IL-10. No 
significant 
changes in 





















To evaluate the 
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there was a 
blunting effect 
after both the 8 











Hess, 2017, USA To compare satiety 
and food intake 
differences between 
mushroom and meat 
consumption.  
Cross-over, 2-










mushroom meal  
(226 g/day) 










had a positive 
effect on 
satiety, but no 





To investigate how 
substituting 
mushrooms for beef 
in a test lunch 
affected energy 
intake, fat intake, 
palatability, appetite, 
satiation and satiety 














mushroom meal  
(339 kcal/day)  
Comparator: Cooked beef 



















daily energy and 
fat intake were 
greater in the 










Lee, 2013, China To investigate the 
association between 
mushroom 
consumption and risk 










Exposure: White button 
mushroom consumption 







cancer risk were 
found at high 











To evaluate the 
effects of white 
button mushroom 
powder on serum 
PSA levels and 
determine the 
tolerability. 
Phase I, clinical 
dose-escalation  
n: 36 
10 m  
(1-58 m) 
68 y  
0% f 





















Hess, 2018, USA To assess mushroom 
consumption 
compared to meat 
on gastrointestinal 
tolerance, short 
chain fatty acid 
(SCFA) production, 
laxation, and fecal 
microbiota. 
Cross-over, 2-










mushroom meal (226 
g/day)  
Comparator: Cooked beef 
















diet resulted in 
higher average 
stool weight and 
a different fecal 
microbiota 
composition 
compared to the 














halitosis and body 






4 w 64 ± 7 y 
51% f 
Problematic 
halitosis, body or 
fecal odor 
Intervention: 
Champignon extract (50 
mg/day OR 500 mg/day 
OR 1000 mg/day) 








Strain during bowel 
movements 
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To investigate the 
physiological and 
biological effects of 
eating mushrooms 





30 d Not reported. Intervention: Cooked 
mushroom (2 g/kg body 
weight/day)  













































































there was a 
blunting effect 
after both the 8 
g and 16 g 
doses.  
Ø 
T2D risk management 
Calvo, 2016, USA To estimate the 
impact of adding 
white button 
mushrooms to daily 









cooked mushrooms (100 
g/day) 
Comparator: Supplement 
1242 IU D3/day OR 7320 
IU D3/day 





































To investigate the 
effect of dietary 
intake of white 
button mushrooms 
on salivary IgA (sIgA) 










mushrooms (100 g/day)  
Comparator: Usual diet 
sIgA:osmality 
sIgA secretion rate 
sIgA concentration  
IgG secretion rate 






















IG: intervention group. CG: comparator group. UV: ultraviolet. PSA: total serum prostate-specific antigen. MetS: metabolic syndrome. 25(OH)D: 25-
hydroxyvitamin D. IL: interleukin. iPTH: parathyroid hormone. TNFα: tumour necrosis factor alpha. HDL: high density lipoprotein cholesterol. LDL: low 
density lipoprotein cholesterol. WBC: white blood cells. RBC: red blood corpuscles. Hb: haemoglobin. PCV: packed cell volume. ORAC: oxygen radical 
absorbance capacity. sCML: serum carboxymethyl-lysine. sMG: serum methylglyoxal. sIgA: secretory immunoglobulin A. IgG: immunoglobulin G. d: 
days. w: weeks. m: months. y: years. f: female. IU: international unit. ↑: significant increase compared with control. ↓: significant decrease compared 
with control. ↔: no significant change compared with control. Study quality +: positive. Ø: neutral. –: negative. * ex-vivo LPS-stimulated cytokine 
production in peripheral mononuclear blood cells (PBMC). ** PHA-induced T-cell proliferation in PBMC. *** 4-arm pooled analysis. a: significant from 
baseline.  
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Table 3. Bioactive components in Agaricus Bisporus mushrooms 
Reference Type Mushroom source 
(wild/cultivated, country) 




Babu, 2013 WBM Cultivated, India Cap Flavonoids 2.173 ± 0.0007 µg/g 
Stipe Flavonoids  1.533 ± 0.005 µg/g 












Tajalli, 2015 WBM Cultivated/wild, Iran Whole (wild)
^
 Flavonoids 3.72 (0.0020) mg CE/g 
Anthocyanins 4.7 (1.2) mg CGEs/100 g 
Flavonoids 4.24 (0.0016) mg CE/g 
Anthocyanins 7.7 (0.5) mg CGEs/100 g 
Flavonoids 2.78 (0.0004) mg CE/g 
Anthocyanins 1.13 (0.2) mg CGEs/100 g 
Flavonoids 5.11 (0.0044) mg CE/g 
Anthocyanins 0.15 (0.01) mg CGEs/100 g 
Whole (cultivated) Flavonoids 3.98 (0.0004) mg CE/g 
Anthocyanins 1.7 (0.2) mg CGEs/100 g 
Flavonoids 4.12 (0.0020) mg CE/g 
Anthocyanins 0.087 (0.1) mg CGEs/100 g 
Flavonoids 4.15 (0.0016) mg CE/g 
Anthocyanins 'very low' (almost 0) mg 
CGEs/100 g  
Flavonoids 4.94 (0.0028) mg CE/g 
Anthocyanins 4.6 (0.9) mg CGEs/100 g 
Singla, 2010 WBM Cultivated, India Whole (raw) Flavonoids (free) 37.12 mg/100 g  
Flavonoids (bound) 64.69 mg/100 g  
Whole (processed) Flavonoids (free) 35.42 mg/100 g 
Flavonoids (bound) 63.72 mg/100 g 
Mircea, 2015 BBM Cultivated, Romania Whole Flavonoids 1.09 (0.02) mg CE/g 
0.97 (0.01) mg CE/g 
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1.52 (0.01) mg CE/g 
Guizani, 2012 WBM Cultivated, Oman Whole Flavonoids 0.76 (0.05) mg 
Jaworska, 2014 WBM Cultivated, Poland Whole (fresh) Flavonoids 142 (8) mg/100 g 
Whole (blanched) Flavonoids  53 (3) mg/100 g 
Whole (culinary treated) Flavonoids 35 (5) mg/100 g  
Gan, 2013 WBM Cultivated, Malaysia, Brazil Extract (60% ethanol) Flavonoids 1.75 (0.26) mg GAE/g 
Extract (aqueous) Flavonoids 1.36 (0.11) mg GAE/g 
Ganguli, 2006 WBM Cultivated, India Whole (raw) Flavonoids 0.079% (0.004) 
Whole (fried 4min) Flavonoids 0.050% (0.002) 
Whole (fried 5min) Flavonoids 0.041% (0.004) 
Whole (fried 6min) Flavonoids 0.038% (0.006) 
Singla, 2012 WBM Cultivated, India Whole (raw) Flavonoids 37.12 mg/100 g 
Whole (2% treated) Flavonoids 31.54 mg/100 g 
Whole (4% treated) Flavonoids 31.53 mg/100 g 
Öztürk, 2011 WBM Cultivated, Turkey Whole Flavonoids 5.12 (0.55) µg QE/mg 
Ozen, 2010 WBM Cultivated, Turkey Flavonoids 0.106 (0.006) mg QE/g 
Anthocyanins 0.17 (0.01) mg/mL 
Rezaeian, 2015 WBM Cultivated/wild, Iran Whole (cultivated) Flavonoids 6.46 (0.13) mg CE/g 
Whole (cultivated) Flavonoids 1.11 (0.24) mg CE/g 
Whole (wild)  ̂ Flavonoids 4.48 (0.05) mg CE/g 
Ng, 2019 WBM Cultivated, India Whole (raw) Flavonoids 78.67 (8.80) mg QE/100 g 
Whole (boiled) Flavonoids 46.89 (1.25) mg QE/100 g 
Whole (microwaved) Flavonoids 43.39 (4.66) mg QE/100 g 
Whole (steamed) Flavonoids 32.83 (4.51) mg QE/100 g 
Whole (pressure-cooked) Flavonoids 59.11 (10.30) mg QE/100 g 
Ng, 2017 WBM Cultivated, Malaysia Whole (raw) Flavonoids 20.2 (2.9) mg Qct/100 g 
Whole (boiled 1.5 min) Flavonoids 12.2 (2.8) mg Qct/100 g  
Whole (boiled 3 min) Flavonoids 11.3 (2.7) mg Qct/100 g  
Whole (boiled 4.5 min) Flavonoids 10.7 (0.7) mg Qct/100 g  
Whole (boiled 6 min) Flavonoids 9.8 (0.4) mg Qct/100 g  
Whole (microwaved 1.5 min) Flavonoids 14.3 (2.4) mg Qct/100 g  
Whole (microwaved (3 min) Flavonoids 7.5 (1.0) mg Qct/100 g  
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Whole (microwaved 4.5 min) Flavonoids 6.1 (1.1) mg Qct/100 g 
Whole (microwaved 6 min) Flavonoids 4.2 (0.5) mg Qct/100 g 
Whole (steamed 1.5 min) Flavonoids 11.2 (3.4) mg Qct/100 g  
Whole (steamed 3 min) Flavonoids 14.4 (5.0) mg Qct/100 g 
Whole (steamed 4.5 min) Flavonoids 12.0 (1.0) mg Qct/100 g  
Whole (steamed 6 min) Flavonoids 13.8 (1.0) mg Qct/100 g  
Whole (pressure-cooked 15 
min) 
Flavonoids 12.7 (0.3) mg Qct/100 g 
Barros, 2018 WBM Cultivated/wild, Portugal Whole^ Flavonoids 1.73 (0.11) mg/g 
Buruleanu, 2018 WBM Cultivated, Romania Cap Flavonoids 6.54 (0.00) mg QE/g 
Flavonoids 7.83 (4.18) mg QE/g 
Stipe Flavonoids 5.23 (0.02) mg QE/g 
Flavonoids 3.26 (0.04) mg QE/g 
BBM Cap Flavonoids 8.43 (0.02) mg QE/g 
Flavonoids 3.5 (0.14) mg QE/g 
Stipe Flavonoids 8.05 (0.04) mg QE/g 
Flavonoids 5.22 (0.06) mg QE/g 
Khan, 2016 WBM Cultivated, India Whole Flavonoids 56.76 μg RE/g 
Jagadish, 2009 WBM Cultivated, India Whole (raw) Flavonoids 16.4 (0.5) mg QE/g 
Whole (boiled) Flavonoids 15.2 (0.2) mg QE/g 
Dhamodhara, 2013 WBM Cultivated, India Whole Flavonoids 10.3 (1.0) mg QE/g 
Um, 2014 WBM Cultivated, South Korea Whole Flavonoids 1636.8 (17.5) mg naringin/100 g  
























Whole Chitin 4.9 mg/100 g 
Choi, 2010 WBM Korea Whole Total glucan 8.97 (0.21) % w/w 
α-glucan 1.13 (0.52) % w/w 
β-glucan 7.83 (0.74) % w/w 
LMW Catechin 15.07 (0.83) mg/g 
Tannic acid 11.58 (0.65) mg/g 
Gallate 9.51 (0.52) mg/g 
HMW Catechin 14.98 (0.34) mg/g 
Tannic acid 11.50 (0.27) mg/g 
Gallate 9.45 (0.22) mg/g 
Dikeman, 2005 WBM Cultivated, USA raw immature β-glucan 0.1% 
cooked immature β-glucan 0.1% 
raw mature β-glucan 0.1% 
cooked mature β-glucan 0.1% 
Crimini raw immature β-glucan 0.1% 
cooked immature β-glucan 0.1% 
raw mature β-glucan 0.1% 
cooked mature β-glucan 0.1% 
Portabella raw immature β-glucan 0.1% 
cooked immature β-glucan 0.1% 
raw mature β-glucan 0.0% 
cooked mature β-glucan 0.2% 
Nitschke, 2011a WBM Cultivated, Germany Whole β-glucan 2.60 g/100 g 
Khan, 2017 WBM Cultivated, India Whole Total glucan 10.045 (0.21) g/100 g 
α-glucan 1.534 (1.56) g/100 g 
β-glucan 8.511 (2.45) g/100 g 
Singh, 2017 WBM Cultivated, India Whole Total glucan 0.78 g/10 g 
Chitin 0.12 g/10 g 
Chitin-glucan complex 1.8 g/10 g 
Portobello Total glucan 3.96 (0.64) 





Portobello Cultivated, Poland Whole Total glucan 3.96 (0.64) 
Crimini Total glucan 3.94 (0.08) 
β-glucan 19.2% 
Sari, 2017 WBM Cultivated, Germany Cap Total glucan 10.051 ± 2.228 g/100 g 
α-glucan 1.547 ± 0.378 g/100 g 
β-glucan 8.605 ± 2.373 g/100 g 
Stipe Total glucan 14.963 (4.979) g/100 g 
α-glucan 2.667 (1.224) g/100 g 
β-glucan 12.296 (4.077) g/100 g 
BBM Cap Total glucan 12.348 (4.514) g/100 g 
α-glucan 3.511 (2.383) g/100 g 
β-glucan 8.837 (3.046) g/100 g 
Stipe Total glucan 14.647 (4.874) g/100 g 
α-glucan 4.568 (2.845) g/100 g 
β-glucan 10.079 (2.230) g/100 g 
Taofiq, 2016 Unknown Portugal Extract Ergosterol 44.79 ± 0.37 mg/g 
Stojkovic, 2014 Unknown Netherlands Cap Ergosterol 138.74 ± 0.61 mg/100 g 
Simon, 2011 WBM Cultivated, Canada Whole Ergosterol 578.2 ± 29.8 mg/100 g 
Vitamin D 5.5 ± 4.6 µg/100 g 
Whole (UV light exposed) Ergosterol 579.5 ± 20.7 mg/100 g 
Vitamin D 579.5 ± 20.7 µg/100 g 
Whole (sunlight exposed) Ergosterol 633.4 ± 17.4 mg/100 g 
Vitamin D 633.4 ± 17.4 µg/100 g  
Shao, 2010 WBM Canada Stage 1 Ergosterol 3.41 mg/g 
Stage 2 Ergosterol 3.32 mg/g 
Stage 3 Ergosterol 3.01 mg/g 
Cap (Stage 3) Ergosterol 3.30 mg/g 
Stipe (Stage 3) Ergosterol 2.33 mg/g 
BBM Canada Stage 1 Ergosterol 4.66 mg/g 
Stage 2 Ergosterol 2.93 mg/g 
Stage 3 Ergosterol 2.49 mg/g 
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Cap (Stage 3) Ergosterol 2.71 mg/g 
Stipe (Stage 3) Ergosterol 2.03 mg/g 
Sapozhnikova, 2014 WBM Cultivated, USA Extract Ergothioneine 0.81-0.92 mg/g 
Ergosterol 4.6-5.2 mg/g 
Vitamin D 179 ± 5 IU/g 
Extract (Low UV) Vitamin D 2156 ± 43 IU/g 
Extract (High UV) Vitamin D 4739 ± 61 IU/g 
BBM Cultivated, USA Extract Ergothioneine 0.37-0.48 mg/g 
Ergosterol 4.6-6.2 mg/g 
Vitamin D 179 ± 4 IU/g 
Extract (Low UV) Vitamin D 1942 ± 30 IU/g 
Extract (High UV) Vitamin D 6292 ± 109 IU/g 
Phillips, 2011 WBM Cultivated, USA Whole Ergosterol 56.3 mg/100 g 
Vitamin D 0.11 ug/100 g 
Crimini Cultivated, USA Whole Ergosterol 61.4 mg/100 mg 
Vitamin D 0.06 ug/100 g 
Portabella Cultivated, USA Cap Ergosterol 62.1 mg/100 g 
Vitamin D 0.25 ug/100 g 
Cap (UV treated) Ergosterol 51.1 mg/100 g 
Vitamin D 11.2 ug/100 g 
Mattila, 2002 WBM Cultivated, Finland Whole Ergosterol 654 mg/100 g 
Vitamin D 0 mg/100 g 
Wild, Finland Whole^ Vitamin D 4.7-194 ug/100 g 
Jasinghe, 2005 WBM Cultivated, Singapore Whole Ergosterol 7.80 ± 0.35 mg/g 
Vitamin D 12.48 ± 0.28 ug/g 
Heleno, 2017 WBM Cultivated, Portugal Extract Ergosterol 36.72 ± 0.01 mg/g 
Hammann, 2016 WBM Cultivated, Germany Whole Ergosterol 443 ± 44 mg/100 g; 90% free 
sterols 
Guan, 2016 WBM Cultivated, Canada Cap 
UV dose: 
Ergosterol 6.12 ± 0.09 mg/g 
0.5 kj/m2 6.05 ± 0.37 mg/g 
1.0 kj/m2 6.11 ± 0.20 mg/g 
2.0 kj/m
2
 5.96 ± 0.16 mg/g 





 5.4 ± 0.29 mg/g 
1.0 kj/m
2
 5.25 ± 0.22 mg/g 
2.0 kj/m
2
 5.2 ± 0.18 mg/g 
BBM Cap 
UV dose: 
Ergosterol 7.59 ± 0.13 mg/g 
0.5 kj/m2 7.61 ± 0.61 mg/g 
1.0 kj/m2 7.64 ± 0.31 mg/g 
2.0 kj/m2 7.69 ± 0.19 mg/g 
Stem 
UV dose: 
Ergosterol 7.56 ± 0.41 mg/g 
0.5 kj/m
2
 7.22 ± 41 mg/g 
1.0 kj/m
2
 7.35 ± 0.29 mg/g 
2.0 kj/m
2
 7.60 ± 0.18 mg/g 
Gasecka, 2018 BBM Cultivated, Poland Extract (Hollander Spawn C9) Ergosterol 26.4 ± 1.5 mg/100 g 
WBM Extract (Sylvan 767) Ergosterol 9.5 ± 1.2 mg/100 g 
Extract (Amycel 2600) Ergosterol 21.7 ± 1.2 mg/100 g 
Extract (Kanmycel 3-1) Ergosterol 36.1 ± 3 mg/100 g 
Extract (Italspawn F599) Ergosterol 4 ± 0.7 mg/100 g 
Extract (Kanmycel K2) Ergosterol 18.4 mg/100 g  
Extract (Sylvan A15) Ergosterol 1.1 ± 0.2 mg/100 g 
Cardoso, 2017 WBM Cultivated, Portugal Cap Ergosterol 17.4 ± 0.1 mg/g 
Cardoso, 2019 Portobello Cultivated, Portugal Whole Ergosterol 216-250 mg/100 g
Barreira, 2014 Portobello Cultivated, Portugal Extract Ergosterol 352 ± 1 mg/100 g 
77 ± 1 mg/100 g 
Alshammaa, 2017 WBM Wild, Iraq Extract^ Ergosterol 27.6675% (w/w) 
Chung, 1998 WBM Cultivated, UK Stipe Chitin 42% 
Hassainia, 2018 WBM Cultivated, France Cap Chitin 7.4 ± 1.2% 
Stipe Chitin 6.4 ± 1.4% 
Gills Chitin 5.9 ± 1.2% 
Manzi, 2001 WBM Cultivated, Italy Whole (fresh, raw) β-glucan 1.4 ± 0.2 mg/100 g 
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Chitin 0.6 ± 0.04 g/100 g 
Whole (fresh, cooked) β-glucan 4.2 ± 0.3 mg/100 g 
Chitin 0.7 ± 0.04 g/100 g 
Whole (deep frozen, raw) β-glucan 1.2 ± 0.6 mg/100 g 
Chitin 0.34 ± 0.01 g/100 g 
Whole (deep frozen, cooked) β-glucan 3.2 ± 0.8 mg/100 g 
Chitin 0.52 ± 0.02 g/100 g 
Whole (canned, raw) β-glucan 1.7 ± 0.2 mg/100 g 
Chitin 0.61 ± 0.05 g/100 g 
Whole (canned, cooked) β-glucan 0.8 ± 0.4 mg/100 g 
Chitin 0.74 ± 0.06 g/100 g 
Nitschke, 2011b WBM Cultivated, Germany Extract Chitin 4.69 ± 0.90 mg/100 g 
Vetter, 2007 WBM Cultivated, Germany Cap (1
st
 flush) Chitin 7.21 ± 0.51% 
Cap (2
nd
 flush) Chitin 7.16 ± 1.0% 
Cap (3
rd
 flush) Chitin 5.63 ± 1.02% 
Stipe (1st flush) Chitin 7.61 ± 0.90% 
Stipe (2nd flush) Chitin 7.29 ± 1.34% 
Stipe (3rd flush) Chitin 6.94 ± 2.23% 
Kalaras, 2017 WBM Cultivated, USA Whole Ergothioneine  0.41 ± 0.18 mg/g 
Crimini 0.47 ± 0.16 mg/g 
Portobello 0.15 mg/g 
Dubost, 2007 WBM Cultivated, USA Whole Ergothioneine 0.21 ± 0.01 mg/g 
Crimini 0.40 ± 0.03 mg/g 
Portobello 0.45 ± 0.03 mg/kg 
Chen, 2012 WBM Cultivated, Taiwan Whole Ergothioneine 932.7 ± 5.0 mg/kg 
WBM: white button mushroom. BBM: brown button mushroom. LMW: low molecular weight. HMW: high molecular weight. * pressurized-water extraction temperatures. 
^ wild mushrooms may naturally receive UV exposure from sunlight compared to cultivated mushrooms unless otherwise specified. a: values estimated from figures. µg: 
micrograms. CGEs: cyanidin-3-glucoside equivalents. CE: catechin equivalents. QE: quercetin equivalents. GAE: gallic acid equivalents. Qct: quercetin. RE: rutin equivalents. 
w/w: weight per weight.  
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Supplementary Material 
Table S1: Search terms 
Medline & Embase (Ovid) 
1 "agaricus".ti,ab. 
2 Agaricus/ 
3 (button adj3 mushroom*).ti,ab. 
4 "common mushroom*".ti,ab. 
5 champignon*.ti,ab. 
6 (cremini* or crimini*).ti,ab. 
7 (portobello* or portabello* or portabella* or portobella*).ti,ab. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 (review or editorial or letter or comment).pt. 
10 8 not 9 
CINHAL 
S9  S1 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 
S8 
TI ( portobello* or portabello* or portabella* or portobella* ) OR AB ( portobello* or 
portabello* or portabella* or portobella* )   
S7  TI ( cremini* or crimini* ) OR AB ( cremini* or crimini* )   
S6  TI agaricus OR AB agaricus   
S5  TI champignon* OR AB champignon*   
S4  TI "common mushroom*". OR AB "common mushroom*".  
S3  TI "button mushroom*" OR AB "button mushroom*"   
S2  TI button adj3 mushroom* OR AB button adj3 mushroom* 
S1  "agaricus"   
Scopus 
( TITLE-ABS-KEY ( agaricus )  OR  TITLE-ABS-KEY ( "button mushroom*" )  OR  TITLE-ABS-
KEY ( champignon* )  OR  TITLE-ABS-KEY ( ( crimini*  OR  cremini* ) )  OR  TITLE-ABS-
KEY ( ( portabello*  OR  portobella*  OR  portobello* ) )  AND 




2 button NEAR/3 mushroom* 
3 (portabello* or portabella* or portobello* or portobella) 
4 
champignon* 
5 (crimini* or cremini*) 
6 ("Agaricus"):ti,ab,kw 
7 MeSH descriptor: [Agaricus] explode all trees 
8 (button mushroom*):ti,ab,kw 
9  (portabello* or portabella* or portobello* or portobella):ti,ab,kw 
10 (champignon*):ti,ab,kw 
11 ((crimini* or cremini*)):ti,ab,kw 
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Table S2. Quality Criteria Checklist for Primary Research 
Relevance Validity 
Study reference R/v q 1 q 2 q 3 q 4 q 1 q 2 q 3 q 4 q 5 q 6 q 7 q 8 q 9 q 10 Overall 
Volman et al, 2010 1 Yes Yes Yes Yes Yes Yes ? ? ? Yes Yes ? Yes ? 
ϴ 
2 Yes Yes Yes Yes Yes Yes ? Yes Yes Yes Yes Yes Yes Yes 
Stephensen et al, 2012 1 Yes Yes Yes Yes Yes Yes Yes ? Yes Yes Yes Yes Yes Yes
+ 
2 Yes Yes Yes Yes Yes Yes Yes ? Yes Yes Yes ? Yes Yes 
Urbain et al, 2011 1 Yes Yes Yes Yes Yes Yes Yes Yes ? Yes Yes ? Yes Yes
+ 
2 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Shanely et al, 2014 1 Yes Yes Yes Yes Yes Yes Yes Yes ? Yes Yes ? No No 
ϴ 
2 Yes Yes Yes Yes Yes Yes ? Yes Yes Yes ? Yes Yes ? 
Jeong et al, 2012 1 Yes Yes Yes Yes Yes Yes Yes No ? Yes Yes ? Yes Yes
+ 
2 Yes Yes Yes Yes Yes Yes Yes ? Yes Yes Yes Yes Yes ? 
Nishihira et al, 2017 1 Yes Yes Yes Yes Yes No Yes Yes ? Yes Yes No No No 
- 
2 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes ? ? ? ?
Cheskin et al, 2008 1 Yes Yes Yes Yes Yes Yes ? ? ? Yes Yes Yes Yes ? 
ϴ 
2 Yes Yes Yes Yes Yes Yes ? ? ? Yes Yes Yes Yes ? 
Hess et al, 2018 1 Yes Yes Yes ? Yes Yes ? Yes No Yes Yes Yes No Yes 
ϴ 
2 Yes Yes Yes ? Yes Yes ? Yes Yes Yes ? Yes Yes Yes 
Hess et al, 2017 1 Yes Yes Yes ? Yes Yes ? Yes No Yes Yes Yes Yes Yes
ϴ 
2 Yes Yes Yes ? Yes Yes ? Yes No Yes ? Yes Yes ? 
Weigand-Heller et al, 
2012 
1 Yes Yes Yes Yes Yes ? Yes Yes No Yes Yes No No Yes 
ϴ 
2 Yes Yes Yes Yes Yes Yes ? Yes Yes Yes No Yes ? Yes 
Keegan et al, 2013 1 Yes Yes Yes Yes Yes No No ? No ? Yes No No Yes 
- 
2 Yes Yes Yes Yes Yes No ? ? Yes ? ? ? ? ? 
Twardowski et al, 2015 1 Yes Yes Yes Yes Yes Yes n/a Yes n/a Yes Yes Yes Yes Yes 
+ 
2 Yes Yes Yes Yes Yes Yes Yes n/a ? Yes Yes Yes Yes ? 
Calvo et al, 2016 1 Yes Yes Yes Yes Yes Yes n/a n/a n/a Yes Yes ? Yes Yes 
+ 
2 Yes Yes Yes Yes Yes n/a n/a n/a n/a ? ? Yes Yes Yes
Lee et al, 2013 1 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes ? 
+ 
2 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
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Abd-Alwahab et al, 2018 1 Yes Yes Yes Yes Yes No No ? ? ? No No No ? 
- 
2 Yes Yes Yes Yes Yes No ? ? ? ? No ? ? ? 
R/v: Reviewer. ?: Unclear. +: Positive. ϴ: Neutral. -: Negative.  n/a: not applicable. 
Relevance 
1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population
group? (NA for some epidemiological studies)
2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about?
3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dietetics practice?
4. Is the intervention or procedure feasible? (NA for some epidemiological studies)
Validity 
1. Was the research question clearly stated?
1.1 Was the specific intervention(s) or procedure (independent variable(s)) identified?
1.2 Was the outcome(s) (dependent variable(s)) clearly indicated?
1.3 Were the target population and setting specified?
2. Was the selection of study subjects/patients free from bias?
2.1 Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and
without omitting criteria critical to the study?
2.2 Were criteria applied equally to all study groups?
2.3 Were health, demographics, and other characteristics of subjects described?
2.4 Were the subjects/patients a representative sample of the relevant population?
3. Were study groups comparable?
3.1 Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT)
3.2 Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline?
3.3 Were concurrent controls used? (Concurrent preferred over historical controls.)
3.4 If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for
by using appropriate adjustments in statistical analysis?
3.5 If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control,
this criterion is not applicable. Criterion may not be applicable in some cross-sectional studies.)
3.6 If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., “gold standard”)?
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4. Was method of handling withdrawals described?
4.1 Were follow up methods described and the same for all groups?
4.2 Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described
for each group? (Follow up goal for a strong study is 80%.)
4.3 Were all enrolled subjects/patients (in the original sample) accounted for?
4.4 Were reasons for withdrawals similar across groups?
4.5 If diagnostic test, was decision to perform reference test not dependent on results of test under study?
5. Was blinding used to prevent introduction of bias?
5.1 In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate?
5.2 Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to
be met.)
5.3 In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded?
5.4 In case control study, was case definition explicit and case ascertainment not influenced by exposure status?
5.5 In diagnostic study, were test results blinded to patient history and other test results?
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were intervening factors
described?
6.1 In RCT or other intervention trial, were protocols described for all regimens studied?
6.2 In observational study, were interventions, study settings, and clinicians/provider described?
6.3 Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect?
6.4 Was the amount of exposure and, if relevant, subject/patient compliance measured?
6.5 Were co-interventions (e.g., ancillary treatments, other therapies) described?
6.6 Were extra or unplanned treatments described?
6.7 Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups?
6.8 In diagnostic study, were details of test administration and replication sufficient?
7. Were outcomes clearly defined and the measurements valid and reliable?
7.1 Were primary and secondary endpoints described and relevant to the question?
7.2 Were nutrition measures appropriate to question and outcomes of concern?
7.3 Was the period of follow-up long enough for important outcome(s) to occur?
7.4 Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures?
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7.5 Was the measurement of effect at an appropriate level of precision? 
7.6 Were other factors accounted for (measured) that could affect outcomes? 
7.7 Were the measurements conducted consistently across groups? 
8. Was the statistical analysis appropriate for the study design and type of outcome indicators?
8.1 Were statistical analyses adequately described the results reported appropriately?
8.2 Were correct statistical tests used and assumptions of test not violated?
8.3 Were statistics reported with levels of significance and/or confidence intervals?
8.4 Was “intent to treat” analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-
response analysis)?
8.5 Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)?
8.6 Was clinical significance as well as statistical significance reported?
8.7 If negative findings, was a power calculation reported to address type 2 error?
9. Are conclusions supported by results with biases and limitations taken into consideration?
9.1 Is there a discussion of findings? 
9.2 Are biases and study limitations identified and discussed? 
10. Is bias due to study’s funding or sponsorship unlikely?
10.1 Were sources of funding and investigators’ affiliations described?
10.2 Was there no apparent conflict of interest?
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Highlights 
 Agaricus bisporus contain glucans, ergosterol, ergothioneine and polyphenols
 Nutrient levels can differ based on mushroom type, cooking method and UVB exposure
 Consuming UVB-exposed mushrooms is similar to taking a vitamin D supplement
 Promising results for metabolic syndrome, immune function, gut health and cancer
Figure 1
